Media Stories

05-July-2023

05-July-2023

05-July-2023

10-July-2022

06-July-2022

05-July-2022

09-June-2022

30-April-2022

29-April-2022

11-July-2020

Biocon Biologics Signs 10-Year Deal With Eris Lifesciences To Expand Patient Access

Biocon Biologics: US Biosimilars Are A Marathon, Not A Sprint

Biocon Biologics Secures US Entry Date For Bmab 1200, A Stelara Biosimilar

Biocon included in S&P Global Sustainability Yearbook 2024

Biocon Biologics focusing on market share gains of biosimilars in key markets

We are focused on consolidating our acquired businesses for the coming fiscal year: Biocon Biologics

Biocon Biologics inks pact with Sandoz for sale of 2 biosimilar products in Australia

Budget ’24 | A vision of ‘Viksit Bharat’, driven by inclusion and innovation: Kiran Mazumdar Shaw

Biocon to commercialize biosimilars in 31 European countries

Biocon Biologics grants Sandoz exclusive rights to market biosimilar adalimumab in Japan

Biocon Biologics completes integration of Viatris’ biosimilars business

Biocon Biologics Clinches Seventh Consecutive Asia IP Elite Recognition

Taking Control Of Our Destiny: Biocon Biologics CEO Tambe Celebrates European Viatris Integration

Biocon Biologics integrates Viatris’ biosimilar biz in 31 European nations

Interview With Shreehas Tambe, MD On Biocon’s Strong Q2 Earnings And Acquisition Plans

Biocon Biologics targets top three biosimilar spot: Shreehas Tambe

Biocon Biologics receives UK regulator’s approval for ophthalmic drug YESAFILI

Biocon Biologics to sell 2 non-core branded formulations businesses to Eris Lifesciences for ₹366 cr

Kedar Upadhye steps in as new CFO of Biocon Biologics

Biocon Biologics integrates Viatris Biosimilars in North America, shares up

Biocon Biologics announces top leadership appointments

Biocon Biologics completes integration of biosimilars business in 70+ emerging markets

Biocon Biologics Ltd launches biosimilar HULIO in US

Biocon Biologics Ltd launches biosimilar HULIO in US

Biocon Biologics Receives EU Good Manufacturing Practice Certification

Biocon Biologics’ antibody drug unit in Bengaluru gets EU GMP certificate

Biocon Biologics receives EU GMP certification for its new biologics manufacturing facility in Bengaluru

Biocon Biologics expects big gains from integration of Viatris business, SII deal

Expect regulatory nods for deal with Serum and Viatris to come by H2: Kiran Mazumdar-Shaw, chairperson, Biocon and Biocon Biologics

Biocon Biologics may close $3.34 billion Viatris deal in Q1

Eyeing over 15% market share in US for insulin Glargine: Shreehas Tambe

Biocon Biologics expects R&D expenses to hover between 10-15% in the next financial year

Biocon Biologics acquires Viatris for $3.33 billion

Biocon Biologics acquires Viatris’ biosimilars business in $3.3 bn deal

R&D expenditure will rise in the coming quarters: Biocon Biologics MD

Insulins access program for young expanded in Dec quarter: Biocon Biologics MD

Biocon Biologics set to reap biosimilar insulin glargine opportunity in US

The Medicine Box: Kiran Mazumdar-Shaw on biosimilar interchangeable status for Biocon’s diabetes drug

Biocon Biologics, Viatris confirm offering steep savings on long-acting insulin through Walgreens Prescription Savings Club

Walgreens to sell Biocon’s insulin Semglee in the U.S.

Biocon Biologics, Viatris launch interchangeable insulin biosimilar for US

Biocon Rating: Hold – Vaccines to complement biosimilar portfolio

Biocon Biologics, Serum Institute Life Sciences announce strategic alliance

Interchangeable insulin to help us compete with big insulin makers: Kiran Mazumdar-Shaw

Shreehas Tambe named Deputy CEO of Biocon Biologics

Biocon Biologics, Viatris get CHMP nod for Abevmy

Biocon Biologics to partner with International Diabetes Federation

Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs

India-based company brings affordable insulin to 2 PH towns

India’s Biocon secures approval to use drug on coronavirus patients

Biosimilar drugs can help us reach $1 billion target soon

Kiran Mazumdar-Shaw named EY World Entrepreneur of 2020

Covid provides larger opportunity to shape the biosimilar landscape

Biocon’s cancer biosimilar gets US FDA acceptance for review

Biocon chief is EY entrepreneur for 2019

Biocon Biologics Eyes $200M. Plans IPO in 2 Yrs: Mazumdar-Shaw

Biocon, partner Mylan launch oncology biosimilar trastuzumab in US

Biocon, Mylan get nod for pegfilgrastim drug

Indian company makes it to top 10 best employers in biotech category

Insulin at ₹7 will be a gamechanger for us

Life-enabling product like insulin should be made affordable: Shaw

Biocon plans to halve insulin prices

Biocon sets $1 billion target for biologics business

Biocon subsidiary acquires Pfizer’s R&D facility in Chennai

Ramp-up of biosimilar portfolio to boost Biocon

Our aim is to be a global leader in biosimilars biz: Biocon Biologics CEO

Biosimilars, research key drivers for Biocon

Trastuzumab’s US launch will be a big opportunity for Biocon-Mylan: Shaw

Biocon’s Bengaluru biologics units get European agency nod

The First Lady of Biotech

Canada clears Mylan & Biocon’s Biosimilar

Biocon drug gets commercial rights to global markets

Biosimilars to help Biocon hit $1bn revenue in FY20

Kiran Mazumdar-Shaw conferred with honorary doctorate from Deakin University, Australia

Research must be promoted in colleges

ET Prime celebrates Women’s Excellence in Business & Innovation

Breakthrough innovation is taking place but we’re not leveraging it

Kiran Mazumdar-Shaw conferred with Honorary Doctorate

Biocon Biologics India appoints Dr. Christiane Hamacher as CEO